| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7300935 | SUMITOMO PHARMA | Thienopyrimidine compounds and use thereof |
Jan, 2025
(9 months from now) | |
| US8058280 | SUMITOMO PHARMA | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2025
(9 months from now) | |
| US11795178 | SUMITOMO PHARMA | Compositions of thienopyrimidine derivatives |
Sep, 2033
(9 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8735401 | SUMITOMO PHARMA | Thienopyrimidine compounds and use thereof |
Feb, 2024
(2 months ago) | |
| US10350170 | SUMITOMO PHARMA | Solid preparation |
Feb, 2036
(11 years from now) | |
| US10449191 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(13 years from now) | |
| US10786501 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(13 years from now) | |
| US11583526 | SUMITOMO PHARMA | Treatment of prostate cancer |
Sep, 2037
(13 years from now) | |
Orgovyx is owned by Sumitomo Pharma.
Orgovyx contains Relugolix.
Orgovyx has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Orgovyx are:
- US8735401
Orgovyx was authorised for market use on 18 December, 2020.
Orgovyx is available in tablet;oral dosage forms.
Orgovyx can be used as treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent, treatment of adult patients with advanced prostate cancer.
Drug patent challenges can be filed against Orgovyx from 18 December, 2024.
The generics of Orgovyx are possible to be released after 29 September, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Treatment: Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate cancer
Dosage: TABLET;ORAL
ORGOVYX family patents
